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ScienceDirectAdvances of epigenetic editing
Rutger A. F. Gjaltema1 and Marianne G. Rots2Abstract
Epigenetic editing refers to the locus-specific targeting of
epigenetic enzymes to rewrite the local epigenetic landscape
of an endogenous genomic site, often with the aim of tran-
scriptional reprogramming. Implementing clustered regularly
interspaced short palindromic repeat–dCas9 greatly acceler-
ated the advancement of epigenetic editing, yielding preclinical
therapeutic successes using a variety of epigenetic enzymes.
,CRISPR/dCas9 Here, were review the current applications of
these epigenetic editing tools in mammalians and shed light on
biochemical improvements that facilitate versatile applications.
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Epigenetic modifications of DNA and histones are
known for their multifaceted contributions to tran-
scriptional regulation. As these modifications are faith-
fully propagated throughout DNA replication [1], they
are considered central players in cellular memory of
transcriptional states. Many efforts in the last decade
have generated a vast understanding of individual
epigenetic modifications and their contribution to
transcriptional regulation. However, standing questions
remain regarding how and which modifications
contribute to a certain transcriptional output. Epige-
netic editing offers powerful tools to dissect thesewww.sciencedirect.comquestions at the endogenous locus level, as well to
function as preclinical tools to engineer gene transcrip-
tion. The foundation of epigenetic editing is formed by
the ability to generate fusion proteins of epigenetic
enzymes or their catalytic domains (CDs)with pro-
grammable DNA-binding platforms such as the clus-
tered regularly interspaced short palindromic repeat
(CRISPR) Cas9 to target these to an endogenous locus
of choice (Figure 1) [2,3]. The enzymatic fusion protein
then dictates the initial deposited modification while
subsequent cross-talk within the local chromatin envi-
ronment likely influences epigenetic and transcriptional
output. In this review, we discuss recent advances of
epigenetic editing in mammals based on the CRISPRe
dCas9 platform, with emphasis on the latest chemical
and biotechnological developments to control temporal
and on-target activity.Epigenetic editing of DNA methylation
DNA methylation (5mC) at CpG islands in promoter
regions is associated with transcriptional repressive
states. Targeting DNA methyltransferases (DNMTs) to
those regions would allow target gene repression
through inducing de novo 5mC. Indeed, the full length or
the CD of human or mouse DNMT3A in fusion with
dCas9 (dCas9eDNMT3A and dCas9eDNMT3ACD,
respectively) introduced de novo 5mC up to w60% at
targeted regions (mostly promoters) which was followed
by inhibition of transcription [4]. In a direct comparison
between full-length dCas9eDNMT3A and the dCas9e
DNMT3ACD, the latter displayed more efficient 5mC
activity, whereas dCas9eDNMT3A induced less off-
target 5mC [5].
For enhanced targeted 5mC, various approaches have
been tested: first, fusions of DNMT3ACD and
DNMT3L, a stimulator of DNMT3A catalytic activity
[6] (dCas9eDNMT3A3 L), could induce w5-fold
more 5mC deposition at various target loci than those
of dCas9eDNMT3ACD [7], although not nearing a
fully methylated state of target regions. Another report
confirmed these observations [8]. As a second
approach, full-length DNMT3A was applied to an
adaptation of the SunTag system [5] to enable the
recruitment of multiple copies of scFv-DNMT3ACD
fusion proteins (Figure 2B) [9]. Despite multimer
recruitment, de novo 5mC was lower than that of a
dCas9eDNMT3ACD fusion. Alternatively, increasing
the nuclear trafficking of dCas9eDNMT3ACDCurrent Opinion in Chemical Biology 2020, 57:75–81
Figure 1
Principle of epigenetic editing. Epigenetic editing with the CRISPR/dCas9 platform involves targeting an effector domain (ED) fused to dCas9 (dCas9-ED)
(a) Upon sgRNA-mediated recruitment to a target location (e.g. promoter) the dCas9-ED is able to rewrite the local epigenetic state such as histone tails
or 5mC (depicted as lollipops) and thereby modify transcriptional activity (b). CRISPR, clustered regularly interspaced short palindromic repeat.
76 Chemical Genetics and Epigeneticsthrough cloning a nucleoplasmin nuclear localization
signal C-terminally of DNMT3ACD improved targeted
5mC from w40 to w60% [10], suggesting that con-
ventional dCas9eDNMT3ACD fusions experience
lower nuclear translocation. In addition, simultaneous
targeting of dCas9 fusions with DNMT3A, DNMT3L,
and the Krüppel associated box (KRAB) repressor has
been successfully applied to induce repressive tran-
scriptional memory [11] and effective epigenetic
reprogramming at CCCTC-binding factor (CTCF)
binding sites [8]. In addition to mammalian DNMTs,
the prokaryotic CpG methyltransferase (M.SssI) has
been explored for targeted DNA methylation. Target-
ing a humanized M.SssI derivative (dCas9eMQ1)
introduced high levels of de novo 5mC (up to w70%)
that was widely spread alongside the target region [12].
However, due to extensive off-target 5mC, further
modifications to M.SssI are required for it to be
exploited for targeted DNA methylation ( ‘Precision
epigenetic editing’).
As various disease-related genes are repressed by DNA
methylation, targeted demethylation would offer
unique therapeutic possibilities. Active DNA deme-
thylation is initiated by ten-eleven translocation diox-
ygenases (TETs) that oxidize 5mC to 5-Current Opinion in Chemical Biology 2020, 57:75–81hydroxymethylcytosine and further intermediates. To
initiate targeted demethylation of 5mC, dCas9 fusions
with TET1CD were targeted to methylated regions
[10,13e17] but with a varied degree of demethylation
efficiencies, likely depending on genetic and chromatin
context, as well as on delivery efficacy of the dCas9
tools. Even despite partial DNA demethylation of
target regions, transcriptional reactivation of the
targeted genes was rather weak, likely caused by
remaining repressive microenvironment (e.g. deacety-
lated histones, H3K9me2) [15]. In addition to cultured
cells, targeted DNA demethylation has also been
applied in preclinical mouse models. For example,
targeted demethylation of CGG-repeats within the
fragile X mental retardation 1 (FMR1) promoter
through lentiviral expression of dCas9-TET1CD in
post-mitotic neurons obtained from patient-derived
induced pluripotent stem cells (iPSCs) restored
FMR1 expression and neuronal function in culture and
was even maintained following engrafting into mouse
brains [19]. In another report, in vivo lentiviral delivery
of dCas9eTET3CD in a kidney fibrosis mouse model
resulted in targeted promoter demethylation and sub-
sequent reactivation of two antifibrotic genes, which
attenuated kidney fibrosis and restored kidney function
[20].www.sciencedirect.com
Figure 2
Enhanced CRISPR–dCas9–based epigenetic editors. (a) Second-generation CRISPR systems contain RNA aptamers (MS2 or PP7) linked to the
sgRNA handle, which recruit their corresponding aptamer coat protein (MCP or PCP, respectively) fused to (epigenetic) effector domains (EDs). (b) The
SunTag system consists of a dCas9 fusion with GCN4 peptide repeats that enable the recruitment of multiple copies of an anti-GCN4-scFv-effector
domain fusion protein. (c) Autonomous intein-mediated bioconjugation of a peptide (e.g. UNC3866, a ligand for CBX proteins) to dCas9 (dCas9–
UNC3866) allows targeted recruitment of the endogenous PRC1 complex. (d) CRISPR-CEM contains either a dCas9-FKBP fusion or recruits FKBP
through sgRNA-aptamers (refer (a)). By supplementing a FK506 derivative that additionally contains a bromodomain ligand, this system recruits
endogenous binding partners (HATs) to the FKBP at CRISPR–dCas9. (e) A degron (AID) fusion with dCas9 can be destabilized upon supplementing its
ligand ABA. Subsequent ubiquitination of the fusion protein leads to rapid proteasomal degradation. (f) The split effector domain approach involves
splitting an epigenetic effector domain in minimum of two compatible subdomains that autonomously reassembled based on proximity at their target sites.
CRISPR, clustered regularly interspaced short palindromic repeat; HAT, histone acetyltransferase; ABA, abscisic acid.; MCP, MS2 coat protein; PCP, PP7
coat protein; CEM, chemical epigenetic modifier.
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78 Chemical Genetics and EpigeneticsTo further improve on the targeted demethylation ef-
fects, adaptations of the dCas9eTET1 system have
been tested. Josipovic et al. [10] performed a side-by-
side comparison of the TET1 fusion orientation and
found an N-terminal fusion to dCas9 to be w2-fold
more efficient than the C-terminal fusion. To maxi-
mize local DNA demethylation activity, Xu et al. [16]
tethered TET1CD to the MS2 coat protein and com-
bined these with MS2eaptamer sgRNAs and the con-
ventional dCas9eTET1CD fusion (Figure 2A). As such,
targeting triple TET1CDs to a target location resulted
in w2-fold more DNA demethylation. In addition,
applying TET1CD to a repurposed SunTag system
(Figure 2B) to recruit three copies of TET1CD allowed
robust demethylation of target genes up to 4-fold higher
than that of the conventional dCas9eTET1CD,
although transcriptional reactivation was still minimal
[18]. Together these reports indicate that single fusions
of dCas9eTET1CD are often not effective enough to
fully overcome remaining repressive chromatin and
reactivate target gene expression. This point has been
addressed by a combinatorial approach targeting
dCas9eTET1CD together with dCas9eVP64 to Sox1,
which resulted in synergistic gene reactivation while the
individual fusions hardly had any effect [17].Epigenetic editing of histones
Next to DNA methylation, gene expression is strongly
associated with histone modifications (e.g. H3K4me1/
H3K27ac for active enhancers; H3K4me3/H3K27ac for
active promoters; H3K79me/H3K36me2/3 for tran-
scribed gene bodies; and H3K9me2/3 or H3K27me3 for
silenced genes). The causative effects of certain histone
modifications in modulating gene expression could
clearly be demonstrated by epigenetic editing: targeting
histone lysine methyltransferases (HKMTs) of
H3K9me2/3 (SUV39H1, G9A) performed particularly
well in repressing gene expression, while H3K27me3
(EZH2) performed slightly less [21]. However, the
transcriptional effects of these fusions were highly
context (gene and cell line) dependent. In proliferating
cells, simultaneous targeting of dCas9eDNMT3A3 L
and dCas9eEZH2 to HER2 induced stable repressive
chromatin (up to 50 days), which was not observed for
the combination dCas9eDNMT3A3 L and dCase
KRAB [22]. Furthermore, targeting EZH2 with the
PP7ePCP aptamer recruitment system (Figure 2A)
induced strong H3K27me3 and repressed target gene
expression up to 65% [23].
Next to writing repressive modifications, removing
activating modifications offers another opportunity to
repress endogenous loci. Indeed, transiently targeting
dCas9eHDAC3 adjacent to H3K27ac peaks at pro-
moters of three genes not only removed histone acety-
lation [24] but induced low, yet significant, target gene
re-pression in a context-dependent manner.Current Opinion in Chemical Biology 2020, 57:75–81Surprisingly, in cells stably expressing dCas9eHDAC3,
only one of the three targeted genes showed strong
deacetylation of H3K27ac and repression.
To interrogate promotereenhancer interactions, several
laboratories targeted a dCas9 fusion with the histone
acetyltransferase p300 (dCas9-p300) to induce
H3K27ac at enhancers, either targeting single elements
[25e27] or delivered as pooled CRISPR screens [28],
which indeed affected transcriptional activation of
neighboring loci. Furthermore, Yan et al [29] targeted a
dCas9 fusion of the H3K4me1 HKMT MLL3 SET
domain (dCas9eMLL3SET) to the Sox2 super
enhancer in MLL3/4 double knockout mouse embry-
onic stem cells (ESCs) and induced de novo H3K4me1.
Following this observation, they detected elevated
cohesin levels, suggesting that MLL3-catalyzed
H3K4me1 facilitates cohesion complex formation at
enhancers and subsequent promoter interactions.
Alternatively, targeting a H3K4me1/2 demethylase
fusion (dCas9eLSD1) to a Tbx3 upstream enhancer in
ESCs lead to reduction of enhancer mark H3K4me2 and
a reduced Tbx3 transcription [30]. Whereas, targeting
dCas9eLSD1 to the Tbx3 promoter did not lead to a
repressive chromatin signature, nor Tbx3 transcriptional
repression, suggesting indeed an enhancer-specific
mode of action for H3K4me2.
To gain more insight into the role of promoter
H3K4me3 in transcriptional activation of repressed
genes, we have targeted the H3K4me3 HKMT
PRDM9 (dCas9ePRDM9) to the transcription start
site of several repressed target genes. Particularly pro-
moters with low levels of 5mC could be reactivated,
although to a low extend [31]. Cotargeting with the
H3K79 HKMT DOT1L slightly improved target gene
expression, indicating an additive behavior of both
H3K4me3 and H3K79me2/3 in transcriptional
activation.Small molecule–assisted epigenetic editing
Conditional control over CRISPRedCas9 activity ben-
efits research related to transcriptional memory and
could potentially improve specificity in therapeutic ap-
plications. In pioneering work, Liszczak et al [32]
implemented bioconjugation of a synthetic PRC1
chromodomain ligand (UNC3866) to dCas9 through
intein-directed protein trans-splicing (Figure 2C) to
recruit endogenous PRC1 complex members to target
genes. Building upon this methodology, Chiarella et al.
[33] repurposed the FK506 binding domain of FKBP12
(FKBP) and its ligand FK506 as a chemical recruitment
system of endogenous histone acetylation machineries.
For instance, a FK506-linked BRD4 ligand (CEM87)
could subsequently bind to dCas9eFKBP and through
BDR4 binding subsequently recruit p300 to target sites
(Figure 2D). Compared with a dCas9-p300 fusion, thiswww.sciencedirect.com
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scription more effectively.
Instead of controlling recruitment, controlling protein
stability of dCas9 fusions offers another level of condi-
tional control. As such, the auxin-inducible degron
(AID) system has been implemented to dCas9ep300
targeting. Upon supplementing abscisic acid (ABA),
AID binds to exogenous expressed plant-specific F-box
protein TIR1 and together recruits an E3 ubiquitin
ligase complex that targets AIDedCas9ep300 for
proteosomal degradation (Figure 2E). With this system,
Kuscu et al. [25] reactivated targeted enhancers that
upon supplementing ABA realized a rapid (up to 12 h)
degradation of AIDedCas9ep300 followed by a decline
in H3K27ac and transcriptional activity of the associated
gene.Precision epigenetic editing
For CRISPR/(d)Cas9 to properly bind DNA, it first
scans the genome for sgRNA seed complementary sites.
Meanwhile, any dCas9-tethered epigenetic enzyme
could potentially perform off-target editing, depending
on the enzyme and its activity. Indeed, in a 5mC
depleted but maintenance competent mouse ESC line,
widespread off-target 5mC by dCas9eDNMT3ACD
was observed after targeting a selection of CpG islands
[34]. It appeared that the DNMTactivity of the fusion
protein is a key contributor to off-target methylation, as
a Dnmt3a mutant (R832E) that affects DNMT multi-
merization and catalytic activity resulted in lower off-
target 5mC and confined methylation to the vicinity of
the targeted sites [7]. Analogous to this, targeting a less
active variant (Q147L, affecting DNA binding) of
M.SssI as a fusion with dCas9 (dCas9eMQ1Q147L)
resulted in no obvious off-target 5mC, offering an
advantage over its wild-type dCas9-MQ1 both in vivo as
in cell cultures [12].
Another approach to enhance on-target epigenetic
editing is to target split epigenetic enzymes, which are
designed and expressed in at least two domains that
upon proximity reassemble into a functional enzyme
(Figure 2F). As such, two separate dCas9 fusions, with
each a split M.SssI domain (dCas9eMN/MC), [35]
were targeted to the SALL2 promoter and induced 5mC
as effective as dCas9eDNMT3ACD. Indeed, compared
with dCas9eDNMT3ACD and negative controls,
background methylation by dCas9eMN/MC splits was
barely detected, although this was not assessed
genomewide. The split-enzyme approach is limited by a
thorough understanding of the 3D structure of an
epigenetic enzyme. Only one other split epigenetic
enzyme has been recently reported, although not
applied yet for epigenetic editing, namely a split-
TET2CD system that upon chemical-inducedwww.sciencedirect.comproximity could perform DNA demethylation at
approximately the same efficiency as wild-type
TET2CD [36].Conclusions
By repurposing the CRISPReCas9 platform, main-
stream application of epigenetic editing has become
more feasible. However, there are still some hurdles that
need to be overcome for epigenetic editing to become a
straightforward tool for manipulating the epigenome.
For instance, targeting CRISPRedCas9 to heterochro-
matin regions is technically challenging due to steric
hindrance with nucleosomes and other heterochromat-
in-associated proteins [37]. In addition, various reports
indicated that local (epi)genetic contexts play an
important role in successes and failures on rewriting a
target locus. Furthermore, suboptimal delivery methods
greatly contribute to the variable results of epigenetic
editing. Despite these current limitations, application of
CRISPRedCas9-based epigenetic editing has made
tremendous progress with several epigenetic domains
seem to function fairly well in a variety of tested cell
types, as well as in vivo. Together this provides a solid
framework to further shape the epigenetic editing
toolbox for future applications in, for instance, clinical
settings.Declaration of competing interests
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